Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

Jun 06 2022

• By Jessica Merrill

Cancer

Related Content

AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

May 05 2022

AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data

Feb 21 2022

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Genentech, Inc.

Additional Topics

Clinical Trials Research & Development ASCO Cancer BioPharmaceutical

More from ASCO

More from Conferences

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window